Novo Nordisk said patients taking a bigger dose of its blockbuster obesity drug lost more weight than those on a lower dose, without experiencing an increase in side-effects.

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

The U.S. government on Friday announced a list of 15 prescription medicines targeted for Medicare price negotiations for 2027, which includes Novo Nordisk's blockbuster weight-loss drug Wegovy. Here's